-
公开(公告)号：US20230110077A1
公开(公告)日：2023-04-13
申请号：US17962976
申请日：2022-10-10
发明人： Pottayil Govindan N. Sasikumar , Muralidhara Ramachandra , Seetharamaiah Setty Sudarshan Naremaddepalli
IPC分类号： C07D271/06 , C07D413/04 , C07D413/06 , C07D413/12 , C07D271/10 , C07K5/087 , A61P35/00 , A61K31/4245 , A61K38/05 , A61K45/06 , C07K5/065
摘要： The present invention relates to 1,2,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.
-
公开(公告)号：US20200289477A1
公开(公告)日：2020-09-17
申请号：US16761964
申请日：2018-10-31
发明人： Pottayil Govindan N. Sasikumar , Muralidhara Ramachandra , Raghuveer K. Ramachandra , Adam S. Lazorchak , Timothy L. Wyant
IPC分类号： A61K31/4245 , A61P35/00
摘要： The present disclosure relates to methods comprising administering compounds that inhibit VISTA and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways with a compound that inhibits TIM-3 and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by VISTA, TIM-3, PD-1, PD-L1, and/or PD-L2.
-
公开(公告)号：US20150125491A1
公开(公告)日：2015-05-07
申请号：US14388584
申请日：2013-03-28
CPC分类号： C07K7/64 , A61K31/395 , A61K38/00 , A61K38/12 , A61K45/06 , C07K14/4747 , C07K14/70503 , A61K2300/00
摘要： The present invention relates to novel cyclic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.
摘要翻译： 本发明涉及作为能够抑制程序性细胞死亡1（PD1）信号传导途径的治疗剂的新型环状化合物。 本发明还涉及治疗剂的衍生物。 本发明还包括所述治疗剂和衍生物用于通过免疫激活治疗疾病的用途，包括抑制由于PD-1，PD-L1或PD-L2引起的免疫抑制信号和使用它们的疗法。
-
公开(公告)号：US11865114B2
公开(公告)日：2024-01-09
申请号：US17018811
申请日：2020-09-11
IPC分类号： A61K31/50 , A61K31/501 , A61P35/00 , G01N33/574
CPC分类号： A61K31/501 , A61P35/00 , G01N33/57434
摘要： The present invention provides a method of treating a disease or disorder with at least one SMARCA2/4 degrader, in a subject who are responders to such treatment based on the presence of tumor specific alterations described therein. The present invention also provides the methods for treating prostate cancer in the subjects who are likely to respond to treatment with SMARCA2/4 degraders.
-
公开(公告)号：US20230081191A1
公开(公告)日：2023-03-16
申请号：US17960586
申请日：2022-10-05
发明人： Pottayil Govindan N. Sasikumar , Muralidhara Ramachandra , Raghuveer K. Ramachandra , Adam S. Lazorchak , Timothy L. Wyant
IPC分类号： A61K31/4245 , A61P35/00
摘要： The present disclosure relates to methods comprising administering compounds that inhibit VISTA and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways with a compound that inhibits TIM-3 and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by VISTA, TIM-3, PD-1, PD-L1, and/or PD-L2.
-
公开(公告)号：US20210077486A1
公开(公告)日：2021-03-18
申请号：US17018811
申请日：2020-09-11
IPC分类号： A61K31/501 , A61P35/00 , G01N33/574
摘要： The present invention provides a method of treating a disease or disorder with at least one SMARCA2/4 degrader, in a subject who are responders to such treatment based on the presence of tumor specific alterations described therein. The present invention also provides the methods for treating prostate cancer in the subjects who are likely to respond to treatment with SMARCA2/4 degraders.
-
公开(公告)号：US20200368210A1
公开(公告)日：2020-11-26
申请号：US16761162
申请日：2018-10-31
发明人： Pottayil Govindan N. Sasikumar , Muralidhara Ramachandra , Seetharamaiah Sethy S. Naremaddepalli , Nagaraj Gowda
IPC分类号： A61K31/4245 , A61K31/5377 , A61K31/454
摘要： The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.
-
公开(公告)号：US20180044329A1
公开(公告)日：2018-02-15
申请号：US15556805
申请日：2016-03-09
发明人： Pottayil Govindan Nair Sasikumar , Muralidhara Ramachandra , Appukkuttan Prasad , Seetharamaiah Setty Sudarshan Naremaddepalli
IPC分类号： C07D413/04 , A61K45/06 , C07D271/07 , A61K31/496 , C07D413/14 , A61K31/4245 , A61K31/497 , C07D271/06 , C07D417/04 , A61K31/454 , A61K31/55
CPC分类号： C07D413/04 , A61K31/4245 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/55 , A61K45/06 , C07D271/06 , C07D271/07 , C07D413/14 , C07D417/04
摘要： The present invention relates to 3-substituted-1,2,4-oxadiazole and thiadiazole compounds of formula (I) or formula (II) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.
-
公开(公告)号：US11497735B2
公开(公告)日：2022-11-15
申请号：US16761964
申请日：2018-10-31
发明人： Pottayil Govindan N. Sasikumar , Muralidhara Ramachandra , Raghuveer K. Ramachandra , Adam S. Lazorchak , Timothy L. Wyant
IPC分类号： A61K31/4245 , A61P35/00 , A61K45/06
摘要： The present disclosure relates to methods comprising administering compounds that inhibit VISTA and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways with a compound that inhibits TIM-3 and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by VISTA, TIM-3, PD-1, PD-L1, and/or PD-L2.
-
公开(公告)号：US20220241248A1
公开(公告)日：2022-08-04
申请号：US17728325
申请日：2022-04-25
发明人： Muralidhara Ramachandra , Pottayil Govindan Nair Sasikumar , Girish Chandrappa Daginakatte , Kiran Aithal Balkudru
IPC分类号： A61K31/4245 , A61P35/00
摘要： The present invention relates to a composition of a CD47-SIRPα blocking agent and one or more anti-cancer agent(s), where the CD47-SIRPα blocking agents are represented by a compound of formula (I). The present invention also relates to a method of treating a cancer in a subject by administering a therapeutically effective amount of a CD47-SIRPα blocking agent represented by formula (I) in combination with one or more anti-cancer agent(s).
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.022 秒)
